Anthraquinone

Repeated dose toxicity: oral

Administrative data

Endpoint:

short-term repeated dose toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

1975-6

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: only study summary available and IUCLID data set summary available

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1976

Report date:

1976

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

no data

GLP compliance:

not specified

Test material

Test material information

Constituent 1

Reference substance name:

Anthraquinone

EC Number:

201-549-0

EC Name:

Anthraquinone

Cas Number:

84-65-1

Molecular formula:

C14H8O2

IUPAC Name:

9,10-dihydroanthracene-9,10-dione

Details on test material:

- Name of test material (as cited in study report): Anthrachinon

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: water and Cremophor

Duration of treatment / exposure:

28 days

Frequency of treatment:

daily

Doses / concentrations

Remarks:

Doses / Concentrations:
2, 10, 20, 50, 250 mg/kg
Basis:
actual ingested

No. of animals per sex per dose:

15 females and 15 males

Control animals:

yes, concurrent vehicle

Details on study design:

Two experiments were performed. The dosage in first experiment was 10, 50, 250 mg/kg. The dosage in second experiment was 2 and 20 mg/kg. The application volume was 10 mL/ kg body weight.

Examinations

Observations and examinations performed and frequency:

CLINICAL OBSERVATIONS: Yes

BODY WEIGHT: Yes

HAEMATOLOGY: Yes

CLINICAL CHEMISTRY: Yes

URINALYSIS: Yes

Results and discussion

Results of examinations

Details on results:

RESULTS
All dose groups: no deaths
2 mg/kg bw/day: no signs of toxicity
10, 20, 50, and 250 mg/kg bw/day: impairment of the general condition, black-colored spleen, splenic congestion, increased relative weights of the liver and the spleen
10 mg/kg bw/day: hepatocyte enlargement
10, 50, and 250 mg/kg bw/day: increased relative renal weights in the females
20, 50, and 250 mg/kg bw/day: decreased body weight gain in the females, erythropenia
50 and 250 mg/kg bw/day: decreased body weight gain in the males, increased relative weights of the thyroid, the heart, the testes and the kidneys in the males, hepatocyte enlargement
250 mg/kg bw/day: decreased relative weights of the ovaries, clinical chemistry: slightly increased concentrations of glutamate-pyruvate transaminase and of glutamate oxalo-acetate transaminase.

Effect levels

Key result

Dose descriptor:

NOAEL

Effect level:

ca. 2 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

clinical signs

organ weights and organ / body weight ratios

Target system / organ toxicity

Critical effects observed:

not specified

Applicant's summary and conclusion

Conclusions:

After administration of the substance orally, impairment of the general condition, black-colored spleen, splenic congestion, increased relative weights of the liver and the spleen were recorded in the treated animals (except the lowest dose level). These histopathological findings were recorded:
10 mg/kg bw/day: hepatocyte enlargement
10, 50, and 250 mg/kg bw/day: increased relative renal weights in the females
20, 50, and 250 mg/kg bw/day: decreased body weight gain in the females, erythropenia
50 and 250 mg/kg bw/day: decreased body weight gain in the males, increased relative weights of the thyroid, the heart, the testes and the kidneys in the males, hepatocyte enlargement
250 mg/kg bw/day: decreased relative weights of the ovaries, clinical chemistry: slightly increased concentrations of glutamate-pyruvate transaminase and of glutamate oxalo-acetate transaminase.